Ibandronate
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Ibandronate
Ibandronate: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Ibandronate, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| osteoporosis |
| postmenopausal osteoporosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 9357L | Bondronat | Tablet 50 mg (as ibandronate sodium mono | Valid |
Safety Considerations
- Related conditions flagged in the knowledge graph (not label text): upper GI conditions (gastritis, duodenitis, oesophagitis, oesophageal ulcer, gastro-oesophageal reflux disease, achalasia and other oesophageal motility disorders), osteonecrosis of the jaw, and disorders of calcium and vitamin D metabolism (osteomalacia, rickets). These need confirmation against the Product Information.
- Drug Interactions (100 interactions identified, all listed here moderate):
- Polyvalent cation products that may reduce oral absorption: calcium salts (carbonate, acetate, citrate, gluconate, lactate and others), aluminium hydroxide, iron, kaolin and attapulgite.
- Amphotericin B formulations.
- Aspirin and the mesalazine class (mesalazine, balsalazide), which may add to GI irritation.
- Exenatide and kanamycin.
- Clinical note: ibandronate can cause hypocalcaemia, which is relevant in patients with arrhythmia risk.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.